

PRESS RELEASE



CytoTools AG wins strong strategic institutional investor as new shareholder

- **Maschmeyer Group acquires a sizeable stake of around 5% in CytoTools AG with the help of Paladin Asset Management GmbH.**
- **Maschmeyer Group signals its strategic interest in assisting the company long term with ongoing financial support.**

Darmstadt, 6 May 2013 – Maschmeyer Group has acquired a substantial stake of around 5% in CytoTools AG, a technology holding in the pharma and medical product sector. In talks with the management of CytoTools AG, Maschmeyer Group also showed an interest in possibly increasing its holding further.

Dr. Mark-Andre Freyberg, CEO of CytoTools AG, views the investment very positively: “In Maschmeyer Group we have gained a strong and successful partner, who has recognised the market potential of our DermaPro[®] product. With its excellent sector knowledge and an exceptional network, and also when it comes to the expansion of clinical studies and the development of our pipeline, Maschmeyer Group has signalled its intention of providing us with continuing support. This gives us greater opportunities to maximise the potential of our product and significantly develop our company.”

In DermaPro[®] and CardioClean[®], CytoTools AG has two outstanding prospective products with great potential in the pipeline, with no other active substances currently offering comparable treatment success. The first registration of DermaPro[®] in the open wound care sector is also imminent, which significantly reduces investment risk.

“An ageing population goes hand in hand with an ever-growing need for medical care. The incidence of skin and blood vessel diseases in particular looks set to rise considerably. In view of the considerably higher chances of recovery they offer, both CytoTools AG products are ideally suited to replace the medications currently available on the market,” said Carsten Maschmeyer.

CytoTools AG increased its capital by around EUR 3.7 million at the beginning of March 2013. These new funds have enabled the company to lay the groundwork for extending the current final study Phase III for its wound care product DermaPro[®] in Europe and India to other indications. The scene is also set for a significant increase in the potential target group. After the success of previous clinical studies on DermaPro[®] in the treatment of diabetic foot, one of the most serious chronic wounds, its effectiveness will now be tested in the initial Phase IIb studies for indication of Ulcus cruris (“open leg ulcer”). This is another chronic wound which is difficult to treat.

PRESS RELEASE



CytoTools

The product may also prove effective in future for simple wounds and superficial injuries, thanks to a 2-3 times faster healing rate combined with disinfecting properties. “Based on our own calculations, the potential value of both DermaPro® and CardioClean®, taken separately, extends far beyond the current capitalisation of CytoTools AG,” as a spokesperson for Paladin Asset Management GmbH stated.

CytoTools AG, previously CytoTools GmbH, is a technology and holding company which holds the following shares in its subsidiaries which carry out product development in the pharmaceutical and medical products field: 59.6% in DermaTools Biotech GmbH (therapy field dermatology, urology) and 46% in CytoPharma GmbH (therapy field cardiovascular disease, cancer). The complete know-how is protected by corresponding basic patents which are maintained worldwide by CytoTools AG and transferred to the subsidiary companies in the form of exclusive licenses.

This release contains specific future-oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.

Contact:

CytoTools AG
Dr. Mark Andre Freyberg
Klappacher Str. 126
64285 Darmstadt, Germany
Tel.: +49-6151-95158-12
Fax: +49-6151-95158-13
E-Mail: freyberg@cytotools.de

Press contact:

cometis AG
Ulrich Wiehle
Unter den Eichen 7
65195 Wiesbaden, Germany
Tel.: +49-611-205855-11
Fax: +49-611-205855-66
E-Mail: wiehle@cometis.de